IRIDEX Net Income From Continuing Ops Over Time
| IRIX Stock | USD 1.46 0.03 2.10% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out IRIDEX Performance and IRIDEX Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IRIDEX. Market participants price IRIDEX higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive IRIDEX assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 0.078 | Return On Assets | Return On Equity |
IRIDEX's market price often diverges from its book value, the accounting figure shown on IRIDEX's balance sheet. Smart investors calculate IRIDEX's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since IRIDEX's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between IRIDEX's value and its price as these two are different measures arrived at by different means. Investors typically determine if IRIDEX is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IRIDEX's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare IRIDEX and related stocks such as Adagio Medical Holdings, Envoy Medical, and Pulmatrix Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADGM | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (19.9 M) | (23.7 M) | (38.1 M) | (38.1 M) | (34.3 M) | (36 M) |
| COCH | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (15.9 M) | (36.5 M) | (20.8 M) | (18.7 M) | (19.7 M) |
| PULM | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (25 M) | (27.8 M) | (18.1 M) | (20.6 M) | (20.6 M) | (19.3 M) | (20.2 M) | (18.8 M) | (16.3 M) | (9.6 M) | (11 M) | (11.5 M) |
| VVOS | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (10.8 M) | (12.1 M) | (20.3 M) | (23.8 M) | (15.4 M) | (11.1 M) | (10 M) | (10.5 M) |
| ASBP | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (597.1 K) | (359.1 K) | (12.5 M) | (11.3 M) | (10.7 M) |
| ALUR | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (37.7 M) | (73.8 M) | (26.1 M) | (23.5 M) | (24.7 M) |
| PALI | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (26.6 M) | (14.3 M) | (12.3 M) | (14.4 M) | (16.6 M) | (17.4 M) |
| NVNO | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (13 M) | (7.6 M) | (9.1 M) | (16.5 M) | (24.7 M) | (24 M) | (21.8 M) | (19.6 M) | (20.6 M) |
| HOTH | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (2.5 M) | (7.7 M) | (7.2 M) | (14.3 M) | (11.4 M) | (9.6 M) | (8.2 M) | (7.4 M) | (7.7 M) |
| IINN | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (7.2 M) | (17 M) | (10.3 M) | (11.3 M) | (11.1 M) | (9.9 M) | (10.4 M) |
IRIDEX and related stocks such as Adagio Medical Holdings, Envoy Medical, and Pulmatrix Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| IRIDEX | IRIX |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 1212 Terra Bella |
| Exchange | NASDAQ Exchange |
USD 1.46
Additional Tools for IRIDEX Stock Analysis
When running IRIDEX's price analysis, check to measure IRIDEX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRIDEX is operating at the current time. Most of IRIDEX's value examination focuses on studying past and present price action to predict the probability of IRIDEX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRIDEX's price. Additionally, you may evaluate how the addition of IRIDEX to your portfolios can decrease your overall portfolio volatility.